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Textilinin-1 (Txln-1), a Kunitz-type serine protease inhibitor, is a 59-amino-acid
polypeptide isolated from the venom of the Australian Common Brown snake
Pseudonaja textilis textilis. This molecule has been suggested as an alternative to
aprotinin, also a Kunitz-type serine protease inhibitor, for use as an anti-
bleeding agent in surgical procedures. Txln-1 shares only 47% amino-acid
identity to aprotinin; however, six cysteine residues in the two peptides are in
conserved locations. It is therefore expected that the overall fold of these
molecules is similar but that they have contrasting surface features. Here, the
crystallization of recombinant textilinin-1 (rTxln-1) as the free molecule and in
complex with bovine trypsin (229 amino acids) is reported. Two organic solvents,
phenol and 1,4-butanediol, were used as additives to facilitate the crystallization
of free rTxln-1. Crystals of the rTxln-1–bovine trypsin complex diffracted to
2.0 A˚ resolution, while crystals of free rTxln-1 diffracted to 1.63 A˚ resolution.
1. Introduction
Venoms from snakes, cone snails, scorpions, spiders and sea
anemones are cocktails of many small proteins or peptides with a
range of biological activities (Lewis & Garcia, 2003). For example,
cone snails have peptides that act as calcium or sodium channel
blockers or bind to the nicotinic acetylcholine receptor (Nielsen et al.,
2000). Small proteins or peptides found in snake venoms include the
PLA2 phospholipases (Kwong et al., 1989) and Kunitz-type serine
protease inhibitors, such as the venom basic protease inhibitor (Chen
et al., 2001) and the textilinins (Masci et al., 2000).
To date, six textilinins from Pseudonaja textilis textilis, the
Australian Common Brown snake, have been identified by cloning
from venom-gland cDNA (Masci et al., 2000). All consist of 60
amino-acid residues. Their sequence identities range from 67 to 93%,
with the identity between textilinin-1 (Txln-1) and textilinin-2
(Txln-2) being the highest. The greatest variation across the six
sequences is observed in the segment between amino-acid residues 17
and 21, which is part of the so-called canonical loop and is the region
that is most likely to make direct contact to the putative target serine
proteases. All of the textilinins have a highly conserved serine/lysine
propeptide cleavage site as well as the characteristic six-cysteine-
residue motif common to Kunitz-type serine protease inhibitors. The
24-amino-acid propeptide sequence is hydrophobic, which suggests
that it facilitates secretion of the protein prior to cleavage. Of the six
textilinins that have been characterized, only Txln-1 and Txln-2 are
effective in reducing blood loss in the mouse-tail model (Filippovich
et al., 2002). A sequence alignment of the textilinins shows that
arginine in position 17 (the residue that binds in the P1 pocket in
serine proteases) is common to Txln-1 and Txln-2, while the other
four textilinins have an asparagine, lysine, glutamate or aspartate in
this position.
Txln-1 has been suggested as an alternative to aprotinin (marketed
as Trasylol) as an anti-bleeding agent during surgical procedures. It is
believed that Txln-1’s anti-bleeding property is a consequence of its
ability to inhibit plasmin; it has a Ki value of 13.5 nM for this enzyme
(Flight et al., unpublished data). Txln-1 is also a potent inhibitor of
trypsin, with a Ki value of 36 nM, and a moderate inhibitor of tissue
kallikrein, with a Ki value of 3 mM (Flight et al., unpublished data).
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No inhibitory activity was observed when the propeptide form of
Txln-1 was used in the plasmin-inhibition assay, suggesting that this
segment blocks the inhibitory site.
Txln-1 is an acidic molecule with a pI of 4.4 (Filippovich et al.,
2002), while aprotinin is basic with a pI of 8.9 (Gebhard et al., 1986).
The reason for this difference is that there are 11 negatively charged
and seven positively charged amino acids in Txln-1, while in aprotinin
there are only four negatively charged and ten positively charged
amino acids. Surprisingly, only four of the charged amino acids are in
identical positions in the two inhibitors. An important difference
between the two inhibitors is that the amino acid that binds to the P1
pocket is lysine in aprotinin, while it is arginine in Txln-1. Overall,
Txln-1 is one amino acid longer than aprotinin, having two extra
amino acids at the amino-terminus but one fewer at the carboxy-
terminus. Thus, the molecular surfaces of the two peptides are
significantly different. In this report, we present preliminary crystal-
lization data for the complex between bovine trypsin and recombi-
nant Txln-1 and the crystallization of free recombinant Txln-1
(rTxln-1). This is the first report detailing the crystallization condi-
tions for any of the textilinins.
2. Material and methods
2.1. Expression and purification of rTxln-1
rTxln-1 (accession No. AAK95519) was produced at BresaGen Ltd
(Adelaide, South Australia). The cloned construct TVWT consisted
of a proprietary N-terminal expression-enhancer sequence (TV), an
internal tryptophan residue (W) and the 59-amino-acid mature
Txln-1 sequence (T). The protein was expressed as inclusion bodies in
Escherichia coli MM294 cells. The inclusion bodies were dissolved at
an alkaline pH at a concentration of 2 mg ml1. Refolding of the
fusion protein was initiated by lowering the pH to 9.5 with 1 M HCl.
The progression of refolding was assessed by RP-HPLC. After 2 h,
cleavage of the TVW moiety was initiated by the addition of
N-chlorosuccinimide (Lischwe & Sung, 1977). The released and
correctly folded rTxln-1 was purified by a combination of phenyl-
Sepharose HP hydrophobic interaction chromatography and
Q-Sepharose HP anion-exchange chromatography (Amersham
Biosciences). The purified rTxln-1 containing fractions from the
Q-Sepharose HP column were pooled and applied onto a Sephadex
G25M column equilibrated with 25 mM Tris–HCl pH 7.8. The rTxln-1
was stored at 277 K in 25 mM Tris–HCl pH 7.8, 50 mg ml1 mannitol
and 0.01% Tween-20. In our laboratory, the purity was assessed by
RP-HPLC to be >97%. Mass spectrometry gave a molecular weight
of 6685 Da, which is within 1 Da of the expected value. Titration of a
trypsin solution with p-nitrophenyl p-guanidinobenzoate (Chase &
Shaw, 1967) in the presence and absence of a sub-equimolar amount
of rTxln-1 gave an estimate of the molar concentration of rTxln-1
which was in excellent agreement with the molar concentration
calculated from the UV spectrum (using "280 = 4560 M
1 cm1,
estimated by the method of Gill & von Hippel, 1989).
2.2. Preparation of the rTxln-1–trypsin complex
For crystallization trials, bovine trypsin (Sigma-Aldrich; Product
No. T1426) and rTxln-1 were incubated for 30 min in the molar ratio
1:1.1. The mixture was purified by FPLC on a Superdex S200 column
equilibrated with 25 mM Tris–HCl pH 7.4 and 50 mM NaCl. The
fractions corresponding to the complex were pooled and assayed
using the chromogenic substrate benzoyl-l-arginyl p-nitroanilide
(BAPNA, Sigma-Aldrich). No significant residual activity could be
measured. The sodium chloride was removed by buffer exchange and
the complex concentrated to 10 mg ml1 for crystallization trials. Free
rTxln-1 was dialysed into 25 mM Tris–HCl pH 7.8 and concentrated
to 40 mg ml1 prior to crystallization trials.
2.3. Crystallization
Crystallization trials of the rTxln-1–bovine trypsin complex and
free rTxln were carried out at 290 K by vapour-phase diffusion using
hanging drops in VDX48 trays from Hampton. All of the wells had a
volume of 200 ml, with the drops consisting of 1 ml well solution and
1 ml protein solution. Hampton Crystal Screens I and II and the
Sigma Crystallization CryoKit (Sigma-Aldrich) were used in the
trials. Sitting drops were also used in attempts to crystallize free
rTxln-1. In these experiments, the concentration of rTxln-1 was
allowed to vary between 5 and 40 mg ml1.
2.4. Cryocooling and data collection
Crystals of the rTxln-1–bovine trypsin complex were transferred
from their growth drop to a new drop containing 70%(v/v) well
solution and 30%(v/v) glycerol. These crystals were then soaked for
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Figure 1
Crystals of the complex between rTxln-1 and trypsin grown from Hampton Crystal
Screen 1 condition No. 27. These crystals are 0.3  0.03  0.01 mm in size. A larger
crystal (see Table 1) was used for data collection.
Table 1
Data-collection and processing statistics.
Values in parentheses are for the highest resolution shell.
rTxln-1–trypsin complex Free rTxln-1
Unit-cell parameters (A˚) a = b = 79.94,
c = 107.83
a = b = 99.70,
c = 77.47
Space group P3121 I422
Temperature (K) 100 100
Resolution (A˚) 42.60–2.00 (2.07–2.00) 38.55–1.63 (1.69–1.63)
Crystal dimensions (mm) 0.3  0.03  0.03 0.3  0.1  0.1
Mosaicity () 0.864 0.572
No. of observations 170492 224218
Unique reflections 27022 24804
Completeness 97.8 (99.8) 99.6 (98.8)
hI/(I)i 13.7 (4.7) 16.9 (7.2)
Rmerge† 0.076 (0.345) 0.075 (0.360)
† Rmerge =
P
h
P
i jIh;i  hIhij=
P
h
P
i Ih;i , where Ih,i is the intensity of the ith
measurement of reflection h and hIhi is the average value over multiple measurements.
5 min in this solution before being looped directly into the cryo-
stream. The free rTxln-1 crystals grew in solutions that did not
require the further addition of cryoprotectant, thus allowing direct
transfer to the cryostream.
X-rays were produced using a Molecular Structure Incorporated
(MSI) FR-E X-ray generator operated at 45 kV and 45 mA. The
images were recorded using an R-AXIS IV++ imaging-plate detector.
For the complex, oscillation images were 0.5 in width, with exposure
times of 240 s. For free rTxln-1, images were 1 in width, with
exposure times of 300 s. During data collection, the crystal-to-
detector distance was 130 mm for the crystals of the complex and
100 mm for the crystals of free Txln-1. Data for the complex were
integrated, scaled and merged with the program CrystalClear 1.3.6
(Pflugrath, 1999), while HKL2000 was used for processing the free
Txln-1 data (Otwinowski & Minor, 1997).
3. Results and discussion
Hampton Crystal Screen I condition Nos. 13, 38, 39 and 27 produced
single crystals of the complex (Fig. 1), which diffracted to 5, 2.5, 2.3
and 2.0 A˚ resolution, respectively. Statistics for the data set to 2.0 A˚
resolution [condition No. 27; 0.1 M Na HEPES pH 7.5, 0.2 M tri-
sodium citrate, 20%(v/v) 2-propanol] are presented in Table 1.
Typically, three to four weeks of incubation were required to allow
these crystals to grow to their maximum size. Crystals often grew in
the presence of a significant amount of precipitate. In general, pH
values in the range 7.5–8.5 and the presence of a low-molecular-
weight organic compound were crucial factors in allowing crystal-
lization to occur. All of the crystals examined belonged to space
group P3121 and had similar unit-cell parameters to the crystal from
condition No. 7 of Hampton Screen 1 (Table 1). If it is assumed that
there is one molecule in the asymmetric unit, VM is 3.2 A˚
3 Da1 and
the solvent content is 62%. Both values are within the range typical
for most proteins (Matthews, 1968).
Initial attempts to crystallize free rTxln-1 at 5 mg ml1 were
unsuccessful, with virtually all of the trials yielding clear solutions.
Subsequent trials at 15 mg ml1 free rTxln-1 were also initially
disappointing, with no crystals obtained in the first month of incu-
bation. A survey of the literature showed that the presence of organic
solvents such as phenol can promote crystallization of small disulfide-
bonded peptides or small molecules. Porcine and human insulin
(Whittingham et al., 1999; Ciszak et al., 1995) and -dendrotoxin
(Skarz˙yn´ski, 1991) are examples where application of these additives
was successful. Therefore, in the next round of trials phenol was
added to a final concentration of 100–200 mM in both the drop and
well solutions. This approach produced three conditions yielding
X-ray diffraction-quality crystals. These were from Sigma CryoKit
condition No. 13 [0.2 M sodium citrate, 0.1 M Tris–HCl pH 8.5, 30%
PEG 400, 10%(v/v) glycerol], Hampton Crystal Screen 2 condition
No. 13 [0.1 M sodium acetate pH 4.6, 0.2 M ammonium sulfate,
30%(w/v) PEG monomethyl ether 2000], Hampton Crystal Screen 1
condition No. 9 [0.1 M trisodium citrate pH 5.6, 0.2 M ammonium
acetate and 30%(w/v) PEG 4000] and Hampton Crystal Screen 1
condition No. 39 [0.1 M HEPES pH 7.5, 2.0 M ammonium sulfate,
2%(v/v) PEG 400]. These crystals generally diffracted to a resolution
between 3.0 and 2.7 A˚. Two other conditions, Hampton Crystal
Screen 2 condition No. 14 (0.1 M trisodium citrate pH 5.6, 2.0 M
ammonium sulfate and 0.2 M potassium sodium tartrate) and Sigma
CryoKit condition No. 13 [0.1 M Tris–HCl pH 8.5, 0.2 M sodium
citrate, 30%(v/v) PEG 400] with 100 mM phenol added also yielded
small needle-shaped crystals, but their diffraction patterns were not
analysed.
After six months incubation in the absence of adding any phenol,
large single crystals appeared in the original drops that were set up
with 15 mg ml1 free rTxln-1. The best of these crystals were
obtained from Hampton Crystal Screen I condition No. 39 [0.1 M Na
HEPES pH 7.5, 2%(v/v) PEG 400 and 2 M ammonium sulfate]. These
crystals diffracted X-rays to 1.63 A˚ resolution (Fig. 2) and belonged
to space group I422 (Table 1). The space group and unit-cell para-
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Figure 3
Crystals of free rTxln-1 grown from Hampton Crystal screen 2 condition No. 14
with 1,4-butanediol as an additive. The largest crystal in the drop is 0.6  0.1 
0.1 mm in size.
Figure 2
A 1 oscillation frame of a cryocooled crystal of rTxln-1. Diffraction data were
observed to 1.63 A˚ resolution. The inset is centred on the 1.7 A˚ resolution ring.
meters were common to all of the crystals of free rTxln-1 that were
tested by X-ray analysis. Similar crystals that diffracted to this reso-
lution were also grown when 10%(v/v) 1,4-butanediol was added to
condition No. 39 (Fig. 3). In other subsequent experiments we have
also demonstrated that the rate of crystallization can be enhanced
significantly by increasing the concentration of free rTxln-1 up to
40 mg ml1.
Based on a VM of 2.4 A˚
3 Da1 and a solvent content of 49%
(Matthews, 1968), it is likely that there are three molecules of free
rTxln-1 in the asymmetric unit. We are now attempting to determine
the three-dimensional structures of these molecules and crystallize
rTxln-1 in complex with plasmin, its putative envenomation target.
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